PureTech Health PLC PureTech Nasdaq Listing Progresses (7941Z)
September 23 2020 - 2:00AM
UK Regulatory
TIDMPRTC
RNS Number : 7941Z
PureTech Health PLC
23 September 2020
23 September 2020
PureTech Health plc
PureTech Plans U.S. Listing on Nasdaq Global Market
PureTech has confidentially submitted a Draft Registration
Statement on Form 20-F with the United States Securities and
Exchange Commission
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to discovering,
developing and commercialising highly differentiated medicines for
devastating diseases, today announces that it has confidentially
submitted a Draft Registration Statement on Form 20-F to the United
States Securities and Exchange Commission ("SEC") in conjunction
with a potential listing of American Depository Shares ("ADSs") on
the Nasdaq Stock Market (the "U.S. Listing"). The U.S. Listing is
expected to take place after the SEC and Nasdaq have completed
their review process.
In light of the Company's strong cash position, the U.S. Listing
will not include the issuance or offering of any shares of the
Company. Following the U.S. Listing, the Company anticipates that
its ADSs would trade on the Nasdaq Global Market, providing access
for those investors who prefer U.S. listed stock.
The Company intends to maintain its premium listing on the
Official List of the UK Financial Conduct Authority and trading on
the main market of the London Stock Exchange in addition to the
potential U.S. listing. The Company's shares will continue to trade
on the London Stock Exchange and be registered with their existing
ISIN number GB00BY2Z0H74 and the Company's ticker symbol in the UK
will continue to be PRTC.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities of the Company, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercialising highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
is comprised of 24 products and product candidates, including two
that have received U.S. Food and Drug Administration (FDA)
clearance and European marketing authorisation. All of the
underlying programmes and platforms that resulted in this pipeline
of product candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company's unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's plans for the U.S. Listing, the commencement of trading
of the ADSs on the Nasdaq Global Market, and timing related
thereto, future prospects, developments, and strategies. The
forward looking statements are not historical facts but are based
on current expectations, estimates and projections and are subject
to known and unknown risks and uncertainties that could cause
actual results, performance and achievements to differ materially
from current expectations, including, but not limited to, those
risks and uncertainties described in the regulatory filings for
PureTech Health plc. Words such as "anticipates," "expects,"
"intends," "plans," "believes," "seeks," "estimates" and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based on assumptions regarding
the present and future business strategies of the company and the
environment in which it will operate in the future. The company
cautions security holders and prospective security holders not to
place undue reliance on these forward-looking statements, which
reflect the view of the company only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Contact:
Investors
Allison Mead Talbot
+1 617 651 3156
amt@puretechhealth.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSEIESEESSESU
(END) Dow Jones Newswires
September 23, 2020 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024